Boy I sure like THIS idea. Adapt and adjust I like it alot.
Abbott currently has a trial under way for a fully bioabsorbable DES called Absorb. It’s the only company to implant such a stent into patients’ coronary arteries. While the benefits have not yet been proved, Capek says that Absorb, which virtually disappears after two years, could allow a patient’s vessel to return to a more natural state. This would make it possible to image the vessel without the obstruction of metal. It would also allow patients to undergo subsequent surgical procedures that aren’t limited by the stent being in place.
that's worth a twirl or two....
Latest news from November. Hopefully they'll do likewise for venous applications in the future. Who can argue with a stent that vanishes into thin air with little threat of thrombosis? Talk about innovation.
http://ducknetweb.blogspot.com/2009/11/ ... trial.html
New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients
ORLANDO, Fla., Nov. 16, 2009 – Abbott today announced three-year data from the first 30 patients in the first phase of the A BSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries. Patients in this first phase of the ABSORB trial experienced no stent thrombosis (blood clots) out to three years and no new major adverse cardiac events (MACE) between six months and three years (3.6 percent at three years). These results were presented at the 2009 American Heart Association's Scientific Sessions.
To build upon the promising results of the ABSORB trial, Abbott is initiating a large-scale trial called ABSORB EXTEND, which will enroll approximately 1,000 patients from up to 100 centers in Europe, Asia Pacific, Canada and Latin America. ABSORB EXTEND is a single-arm study designed to further evaluate the performance of Abbott's proprietary fully bioabsorbable stent technology. The study will enroll patients with more complex coronary artery disease and is slated to begin enrolling before the end of the year.
"Abbott's bioabsorbable stent has the potential to be a major breakthrough for coronary artery disease patients. The data show that patients continue to do well three years after treatment with the bioabsorbable coronary stent," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands, and principal investigator for the ABSORB trial. "The strong results confirm my belief that bioabsorbable technology is the next revolution in interventional cardiology."